NASDAQ:AGIO Agios Pharmaceuticals (AGIO) Stock Price, News & Analysis → This military-backed stock “owns” AI market (From Porter & Company) (Ad) Free AGIO Stock Alerts $36.34 -1.20 (-3.20%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$36.14▼$38.3350-Day Range$27.55▼$38.8152-Week Range$19.80▼$39.70Volume933,084 shsAverage Volume770,967 shsMarket Capitalization$2.06 billionP/E RatioN/ADividend YieldN/APrice Target$35.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Agios Pharmaceuticals alerts: Email Address Agios Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside3.7% Downside$35.00 Price TargetShort InterestHealthy10.97% of Float Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment0.24Based on 23 Articles This WeekInsider TradingSelling Shares$445,716 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($5.11) to ($5.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.90 out of 5 starsMedical Sector660th out of 928 stocksPharmaceutical Preparations Industry309th out of 437 stocks 1.3 Analyst's Opinion Consensus RatingAgios Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAgios Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Agios Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted10.97% of the float of Agios Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAgios Pharmaceuticals has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Agios Pharmaceuticals has recently decreased by 6.61%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAgios Pharmaceuticals does not currently pay a dividend.Dividend GrowthAgios Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAgios Pharmaceuticals has received a 75.34% net impact score from Upright. Agios Pharmaceuticals seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Creating knowledge". The positive contribution in the "Physical diseases" impact category is mostly driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Clinical research services for metabolic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Agios Pharmaceuticals is -0.81. Previous Next 2.4 News and Social Media Coverage News SentimentAgios Pharmaceuticals has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Agios Pharmaceuticals this week, compared to 3 articles on an average week.MarketBeat Follows8 people have added Agios Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Agios Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $445,716.00 in company stock.Percentage Held by InsidersOnly 4.93% of the stock of Agios Pharmaceuticals is held by insiders.Read more about Agios Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Agios Pharmaceuticals are expected to decrease in the coming year, from ($5.11) to ($5.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agios Pharmaceuticals is -5.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agios Pharmaceuticals is -5.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAgios Pharmaceuticals has a P/B Ratio of 2.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Agios Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wealthpin ProThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. About Agios Pharmaceuticals Stock (NASDAQ:AGIO)Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Read More AGIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AGIO Stock News HeadlinesJune 2 at 1:50 AM | americanbankingnews.comAgios Pharmaceuticals, Inc. Forecasted to Earn Q4 2024 Earnings of ($1.68) Per Share (NASDAQ:AGIO)May 30 at 4:05 PM | globenewswire.comAgios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024May 30 at 5:48 AM | americanbankingnews.comAgios Pharmaceuticals (NASDAQ:AGIO) Sets New 52-Week High at $39.70May 30 at 4:20 AM | americanbankingnews.comAgios Pharmaceuticals (NASDAQ:AGIO) Upgraded to Hold at StockNews.comMay 28, 2024 | msn.comRoyalty Pharma Flat on Buying into AgiosMay 28, 2024 | finance.yahoo.comAgios cashes in on cancer drug again with $905M Royalty Pharma dealMay 28, 2024 | msn.comAgios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break OutMay 28, 2024 | finance.yahoo.comAgios Breaks Out On 'Buffed Up' Financials After Inking Massive Brain Cancer DealMay 28, 2024 | finanznachrichten.deRoyalty Pharma plc: Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 MillionMay 28, 2024 | markets.businessinsider.comAgios Pharma Stock Climbs On Royalty Pharma's Deal To Buy Royalty Stake In VorasidenibMay 28, 2024 | msn.comAgios in pact with Royalty Pharma for brain tumor candidateMay 28, 2024 | finance.yahoo.comAgios Announces $905 Million Purchase Agreement for Vorasidenib RoyaltyMay 23, 2024 | americanbankingnews.comZacks Research Research Analysts Increase Earnings Estimates for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)May 14, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Hold Rating on Inovio Pharmaceuticals (INO)May 14, 2024 | globenewswire.comAgios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid CongressMay 6, 2024 | finance.yahoo.comAgios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024May 5, 2024 | finance.yahoo.comEarnings Beat: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMay 4, 2024 | finance.yahoo.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Call TranscriptMay 3, 2024 | finance.yahoo.comAgios Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 3, 2024 | globenewswire.comAgios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024May 3, 2024 | finance.yahoo.comQ1 2024 Agios Pharmaceuticals Inc Earnings CallMay 2, 2024 | seekingalpha.comAgios Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 2, 2024 | investorplace.comAGIO Stock Earnings: Agios Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024May 2, 2024 | chron.comAgios Pharmaceuticals: Q1 Earnings SnapshotMay 2, 2024 | finance.yahoo.comAgios Pharmaceuticals Reports Q1 2024 Earnings: Narrower Loss than Expected with Strong Revenue ...See More Headlines Receive AGIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today6/02/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AGIO CUSIPN/A CIK1439222 Webwww.agios.com Phone(617) 649-8600FaxN/AEmployees383Year FoundedN/APrice Target and Rating Average Stock Price Target$35.00 High Stock Price Target$42.00 Low Stock Price Target$30.00 Potential Upside/Downside-3.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($6.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-352,090,000.00 Net Margins-1,199.26% Pretax Margin-1,199.26% Return on Equity-41.41% Return on Assets-36.36% Debt Debt-to-Equity RatioN/A Current Ratio12.84 Quick Ratio12.39 Sales & Book Value Annual Sales$26.82 million Price / Sales76.92 Cash FlowN/A Price / Cash FlowN/A Book Value$13.10 per share Price / Book2.77Miscellaneous Outstanding Shares56,770,000Free Float53,974,000Market Cap$2.06 billion OptionableOptionable Beta0.81 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Brian M. Goff M.B.A. (Age 55)CEO & Director Comp: $1.23MMs. Cecilia Jones (Age 49)Chief Financial Officer Comp: $403.36kMr. James William Burns (Age 46)Corporate Secretary & Chief Legal Officer Comp: $660.33kDr. Sarah Gheuens M.D. (Age 44)Ph.D., Chief Medical Officer and Head of Research & Development Comp: $769.2kDr. Lewis Clayton Cantley Ph.D. (Age 75)Co-Founder & Member of Scientific Advisory Board Comp: $50kDr. Tak Wah Mak D.Sc. (Age 78)FRSC, Ph.D., Co-Founder & Member of Scientific Advisory Board Dr. Craig B. Thompson M.D. (Age 71)Co-Founder & Chairman of Scientific Advisory Board Dr. Shin-San Su Ph.D. (Age 68)Co-Founder & Member of Scientific Advisory Board Mr. T. J. Washburn Jr. (Age 43)Principal Accounting Officer Dr. Clive Patience Ph.D. (Age 60)Chief Technical Operations Officer More ExecutivesKey CompetitorsInsmedNASDAQ:INSMAscendis Pharma A/SNASDAQ:ASNDCerevel TherapeuticsNASDAQ:CERELegend BiotechNASDAQ:LEGNIntra-Cellular TherapiesNASDAQ:ITCIView All CompetitorsInsiders & InstitutionsFarallon Capital Management LLCBought 1,423,000 shares on 5/24/2024Ownership: 9.848%Tidal Investments LLCBought 32,336 shares on 5/17/2024Ownership: 0.057%Walleye Trading LLCSold 3,200 shares on 5/17/2024Ownership: 0.000%California State Teachers Retirement SystemSold 2,947 shares on 5/16/2024Ownership: 0.098%Caxton Associates LPBought 37,189 shares on 5/16/2024Ownership: 0.066%View All Insider TransactionsView All Institutional Transactions AGIO Stock Analysis - Frequently Asked Questions Should I buy or sell Agios Pharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AGIO shares. View AGIO analyst ratings or view top-rated stocks. What is Agios Pharmaceuticals' stock price target for 2024? 4 brokers have issued twelve-month price objectives for Agios Pharmaceuticals' stock. Their AGIO share price targets range from $30.00 to $42.00. On average, they anticipate the company's share price to reach $35.00 in the next twelve months. This suggests that the stock has a possible downside of 3.7%. View analysts price targets for AGIO or view top-rated stocks among Wall Street analysts. How have AGIO shares performed in 2024? Agios Pharmaceuticals' stock was trading at $22.27 at the beginning of 2024. Since then, AGIO shares have increased by 63.2% and is now trading at $36.34. View the best growth stocks for 2024 here. Are investors shorting Agios Pharmaceuticals? Agios Pharmaceuticals saw a decline in short interest in May. As of May 15th, there was short interest totaling 6,080,000 shares, a decline of 6.6% from the April 30th total of 6,510,000 shares. Based on an average daily trading volume, of 717,300 shares, the days-to-cover ratio is presently 8.5 days. Currently, 11.0% of the shares of the stock are short sold. View Agios Pharmaceuticals' Short Interest. When is Agios Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our AGIO earnings forecast. How were Agios Pharmaceuticals' earnings last quarter? Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) released its quarterly earnings data on Thursday, May, 2nd. The biopharmaceutical company reported ($1.45) earnings per share for the quarter, beating the consensus estimate of ($1.65) by $0.20. The biopharmaceutical company earned $8.19 million during the quarter, compared to analyst estimates of $8.37 million. Agios Pharmaceuticals had a negative net margin of 1,199.26% and a negative trailing twelve-month return on equity of 41.41%. The firm's revenue for the quarter was up 46.0% on a year-over-year basis. During the same period in the prior year, the business earned ($1.47) earnings per share. What ETFs hold Agios Pharmaceuticals' stock? ETFs with the largest weight of Agios Pharmaceuticals (NASDAQ:AGIO) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), WisdomTree BioRevolution Fund (WDNA), Tema Oncology ETF (CANC), ALPS Medical Breakthroughs ETF (SBIO), Harbor Corporate Culture Small Cap ETF (HAPS), Invesco Nasdaq Future Gen 200 ETF (QQQS), First Trust Small Cap Growth AlphaDEX Fund (FYC) and Jpmorgan Healthcare Leaders ETF (JDOC). What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO? 11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Agios Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX). Who are Agios Pharmaceuticals' major shareholders? Agios Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Farallon Capital Management LLC (9.85%), Vanguard Group Inc. (9.81%), Bellevue Group AG (7.06%), Price T Rowe Associates Inc. MD (3.55%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (1.95%) and Assenagon Asset Management S.A. (0.81%). Insiders that own company stock include Brian Goff, Carman Alenson, Cecilia Jones, Christopher Bowden, David P Schenkein, Jacqualyn A Fouse, James William Burns, Kaye I Foster-Cheek, Sarah Gheuens, Theodore James Jr Washburn and Tsveta Milanova. View institutional ownership trends. How do I buy shares of Agios Pharmaceuticals? Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AGIO) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsElon to Transform U.S. Economy? Porter & CompanyWrite this ticker symbol down…StocksToTrade Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.